Overview

A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed Condition

Status:
Completed
Trial end date:
2023-02-03
Target enrollment:
Participant gender:
Summary
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6013 and each component in healthy adult volunteers in fed condition.
Phase:
Phase 1
Details
Lead Sponsor:
Dong Wha Pharmaceutical Co. Ltd.
Treatments:
Linagliptin
Metformin